pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. That process is also due to complete before year-end, said Leschly.

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

SEPTEMBER 14, 2022

Meanwhile, a third gene therapy candidate – SPVN30, which combines the gene sequences in SPVN06 and SPVN20 – is in early development for RP. The post SparingVision raises €75m for eye disease gene therapies appeared first on.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52